
Neurogene Inc (NGNE) Stock Forecast & Price Target
Neurogene Inc (NGNE) Analyst Ratings
Bulls say
Neurogene is a clinical-stage biotechnology company with a differentiated product portfolio of genetic medicines for rare neurological diseases. With a focus on safety and efficacy, the company's proprietary technology, EXACT, has shown potential in treating Rett syndrome and CLN5 Batten disease. The recent completion of a $135M financing extends cash runway into 2029, while the initiation of a Process Performance Qualification campaign and plans for commercial readiness activities show strong execution. The upcoming readout of 12-month data from the Embolden trial in 2027 and NGN-401's potential over competitor TSHA-102 should drive further valuation catch-up.
Bears say
Neurogene is currently a clinical-stage biotechnology company with a strong balance sheet and enough cash on hand to execute their pivotal readout without needing to raise additional funds. However, the upcoming mid-2026 Phase 1/2 update for their lead drug candidate NGN-401, targeting Rett syndrome, will be a key catalyst as investors will be focused on the durability and change in function over time. While the Phase 1/2 data has been promising, with no skills lost and multi-domain gains, the 12+ month follow-up for all 10 participants will be closely watched to see if the initial gains persist and translate into daily function.
This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.
Neurogene Inc (NGNE) Analyst Forecast & Price Prediction
Start investing in Neurogene Inc (NGNE)
Order type
Buy in
Order amount
Est. shares
0 shares